8-K//Current report
CorMedix Inc. 8-K
Accession 0001213900-26-002350
$CRMDCIK 0001410098operating
Filed
Jan 7, 7:00 PM ET
Accepted
Jan 8, 8:15 AM ET
Size
297.5 KB
Accession
0001213900-26-002350
Research Summary
AI-generated summary of this filing
CorMedix Inc. Reports Preliminary 2025 Results; CEO Becomes Board Chairman
What Happened
- CorMedix Inc. announced preliminary financial results for the quarter and year ended December 31, 2025 in a press release dated January 8, 2026; these results are preliminary and subject to completion of audit and accounting procedures and may change.
- Separately, on January 5, 2026 the company and CEO Joseph Todisco executed an amended and restated executive employment agreement; the Board approved Mr. Todisco’s appointment as Chairman of the Board effective January 8, 2026.
Key Details
- Preliminary results: press release issued January 8, 2026 (Exhibit 99.1); results are unaudited and subject to adjustment.
- CEO pay and bonus: Mr. Todisco’s base salary increased from $665,000 to $750,000 effective January 1, 2026; his target annual bonus rose from 65% to 75% of base salary beginning in fiscal 2026.
- Severance and equity protections: if terminated by the company without Cause (or he leaves for Good Reason), he is eligible for 18 months’ base-salary continuation (or, if within 24 months after a Corporate Transaction, 200% of base salary plus target bonus paid over 24 months), prorated bonus for the year of termination, subsidized COBRA up to 18 months (24 months after a Corporate Transaction), and acceleration of certain unvested equity (with full acceleration if termination occurs within 24 months of a Corporate Transaction).
- Governance and restrictions: employment agreement includes customary confidentiality, non-disparagement, non-competition and non-solicitation covenants that apply during employment and for 18 months after termination. A separate January 8, 2026 press release announced additional Board and leadership updates (Exhibit 99.2).
Why It Matters
- Earnings: the preliminary Q4 and full-year results are the most immediate material update for investors; because they are unaudited and subject to change, watch for the finalized figures in audited filings (10-K/10-Q) that may affect valuation and trading.
- Leadership and governance: the CEO’s elevation to Board Chairman consolidates leadership and may influence strategic direction and investor communication.
- Compensation and potential cost impact: the higher base salary, larger bonus target and severance protections increase potential near-term and post-termination compensation exposure, which could affect future operating expenses and governance considerations.
Documents
- 8-Kea0272149-8k_cormedix.htmPrimary
CURRENT REPORT
- EX-99.1ea027214901ex99-1_cormedix.htm
PRESS RELEASE ISSUED BY CORMEDIX INC., DATED JANUARY 8, 2026
- EX-99.2ea027214901ex99-2_cormedix.htm
PRESS RELEASE ISSUED BY CORMEDIX INC., DATED JANUARY 8, 2026
- GRAPHICex99-1_001.jpg
GRAPHIC
- GRAPHICex99-2_001.jpg
GRAPHIC
- EX-101.PREcrmd-20260105_pre.xml
XBRL PRESENTATION FILE
- EX-101.LABcrmd-20260105_lab.xml
XBRL LABEL FILE
- EX-101.SCHcrmd-20260105.xsd
XBRL SCHEMA FILE
- XMLR1.htm
IDEA: XBRL DOCUMENT
- XMLShow.js
IDEA: XBRL DOCUMENT
- XMLreport.css
IDEA: XBRL DOCUMENT
- XMLFilingSummary.xml
IDEA: XBRL DOCUMENT
- JSONMetaLinks.json
IDEA: XBRL DOCUMENT
- ZIP0001213900-26-002350-xbrl.zip
IDEA: XBRL DOCUMENT
- XMLea0272149-8k_cormedix_htm.xml
IDEA: XBRL DOCUMENT
Issuer
CorMedix Inc.
CIK 0001410098
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001410098
Filing Metadata
- Form type
- 8-K
- Filed
- Jan 7, 7:00 PM ET
- Accepted
- Jan 8, 8:15 AM ET
- Size
- 297.5 KB